iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update
Yahoo Finance · May 12, 2026 · iBio, Inc. Common Stock (IBIO)
Received regulatory clearance to initiate its Phase 1 clinical trial of IBIO-600 in Australia Announced a strategic pipeline expansion into pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF) of its bispecific antibody Reported new preclinical data from its obese non-human primate (NHP) study evaluating IBIO-610, with visceral fat reduced by 6.7% and total fat mass by 5.2% SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-dri
Not investment advice. Cached headline, not a full reprint.